293 related articles for article (PubMed ID: 38026157)
1. Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L; Chen N; Dai L; Peng X
iScience; 2023 Nov; 26(11):108192. PubMed ID: 38026157
[TBL] [Abstract][Full Text] [Related]
2. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
4. Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP; Cao Y; Cai J; Zhang YC; Zou QH; Wang JN; Fang Y; Wang JH; Guo SB; Cai QQ
J Hematol Oncol; 2023 Jul; 16(1):78. PubMed ID: 37480137
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
6. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
Hu B; Oki Y
Front Oncol; 2018; 8():139. PubMed ID: 29761078
[TBL] [Abstract][Full Text] [Related]
7. How we treat NK/T-cell lymphomas.
Tse E; Zhao WL; Xiong J; Kwong YL
J Hematol Oncol; 2022 Jun; 15(1):74. PubMed ID: 35659326
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
9. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
Li F; Chen Y; Pang M; Yang P; Jing H
Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
Tse E; Au-Yeung R; Kwong YL
Expert Rev Hematol; 2019 Nov; 12(11):927-935. PubMed ID: 31487202
[No Abstract] [Full Text] [Related]
12. Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.
Tse E; Fox CP; Glover A; Yoon SE; Kim WS; Kwong YL
Semin Hematol; 2022 Oct; 59(4):198-209. PubMed ID: 36805888
[TBL] [Abstract][Full Text] [Related]
13. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
[TBL] [Abstract][Full Text] [Related]
14. Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.
Chan JY; Lim JQ; Ong CK
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440582
[TBL] [Abstract][Full Text] [Related]
15. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma.
Zheng M; Yu L; Hu J; Zhang Z; Wang H; Lu D; Tang X; Huang J; Zhong K; Wang Z; Li Y; Guo G; Liu S; Tong A; Yang H
Transl Oncol; 2020 May; 13(5):100770. PubMed ID: 32298986
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]